secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0000950170-23-057745
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio Q3 net loss $177M; acoramidis NDA filing by year-end
--------------------------------------------------------------

- Net loss attributable to common stockholders $177M ($1.08 per share) vs $137M ($0.93) YoY.
- Revenue $4.1M, up from $0.3M YoY; operating costs $161.8M vs $129.5M.
- Cash, equivalents, marketable securities $505.2M; raised $316M gross via ATM and PIPE.
- NDA for acoramidis (ATTR-CM) to be filed with FDA by end of 2023; Phase 3 win ratio 1.8 (p<0.0001).
- Regulatory alignment with FDA/EMA for infigratinib in achondroplasia; Phase 3 trial start expected in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000095017023057745/0000950170-23-057745-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000095017023057745/bbio-20231102.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-057745

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer